A61K 39/00
Medicinal preparations containing antigens or antibodies
Official title: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
A61K39/00 (Medicinal preparations containing antigens or antibodies) appears on 50,644 US grants and 85,295 published applications in this corpus.
Search patents in A61K- Granted patents
- 50,644
- Published applications
- 85,295
- Assignees
- 15,376
- Inventors
- 98,657
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 47 | 0 |
| 1977 | 53 | 0 |
| 1978 | 51 | 0 |
| 1979 | 68 | 0 |
| 1980 | 87 | 0 |
| 1981 | 79 | 0 |
| 1982 | 79 | 0 |
| 1983 | 61 | 0 |
| 1984 | 80 | 0 |
| 1985 | 77 | 0 |
| 1986 | 80 | 0 |
| 1987 | 124 | 0 |
| 1988 | 134 | 0 |
| 1989 | 130 | 0 |
| 1990 | 111 | 0 |
| 1991 | 146 | 0 |
| 1992 | 195 | 0 |
| 1993 | 202 | 0 |
| 1994 | 190 | 0 |
| 1995 | 208 | 0 |
| 1996 | 276 | 0 |
| 1997 | 547 | 0 |
| 1998 | 857 | 0 |
| 1999 | 897 | 0 |
| 2000 | 880 | 0 |
| 2001 | 945 | 246 |
| 2002 | 888 | 1656 |
| 2003 | 806 | 2976 |
| 2004 | 697 | 2369 |
| 2005 | 622 | 2259 |
| 2006 | 905 | 2069 |
| 2007 | 955 | 1968 |
| 2008 | 1020 | 2158 |
| 2009 | 1131 | 2607 |
| 2010 | 1388 | 2855 |
| 2011 | 1412 | 2888 |
| 2012 | 1540 | 2761 |
| 2013 | 1686 | 2978 |
| 2014 | 1981 | 3331 |
| 2015 | 2039 | 3266 |
| 2016 | 2207 | 3731 |
| 2017 | 2428 | 3885 |
| 2018 | 2419 | 4035 |
| 2019 | 2565 | 4366 |
| 2020 | 2801 | 4610 |
| 2021 | 2763 | 5103 |
| 2022 | 2548 | 5230 |
| 2023 | 2379 | 5048 |
| 2024 | 2584 | 5407 |
| 2025 | 2583 | 4354 |
| 2026 | 1693 | 3139 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 2039/505Comprising antibodiesIndexing code19,429
- A61K 39/395Antibodies12,866
- A61K 2039/51Comprising whole cells, viruses or dna/rnaIndexing code10,921
- A61K 39/12Viral antigens8,011
- A61K 2039/555Medicinal preparations containing antigens or antibodies: characterised by a specific combination antigen/adjuvantIndexing code7,629
- A61K 39/0005Vertebrate antigens6,117
- A61K 39/02Bacterial antigens5,148
- A61K 39/39Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives4,194
All 29 subgroupsShow fewer
- A61K 2039/57Medicinal preparations containing antigens or antibodies: characterised by the type of responseIndexing code4,098
- A61K 2039/545Medicinal preparations containing antigens or antibodies: characterised by the dose, timing orIndexing code4,047
- A61K 2039/54Medicinal preparations containing antigens or antibodies: characterised by the route of administrationIndexing code4,021
- A61K 2039/60Characteristics by the carrier linked to the antigenIndexing code3,587
- A61K 2039/55Medicinal preparations containing antigens or antibodies: characterised by the host/recipientIndexing code2,561
- A61K 2039/70Multivalent vaccineIndexing code1,995
- A61K 2039/58Raising an immune response against a target which is not the antigenIndexing code1,495
- A61K 39/385Haptens or antigens, bound to carriers1,088
- A61K 39/002Protozoa antigens801
- A61K 2039/62Medicinal preparations containing antigens or antibodies: characterised by the link between antigenIndexing code727
- A61K 2039/80Vaccine for a specifically defined cancerIndexing code701
- A61K 39/35Allergens670
- A61K 2039/64Medicinal preparations containing antigens or antibodies: characterised by the architecture of theIndexing code373
- A61K 39/0002Fungal antigens222
- A61K 39/0003Invertebrate antigens178
- A61K 39/118Chlamydiaceae135
- A61K 39/0013Therapeutic immunisation against small organic molecules88
- A61K 39/0016Combination vaccines based on diphtheria-tetanus-pertussis80
- A61K 39/0015Combination vaccines based on measles-mumps-rubella25
- A61K 39/38Antigens from snakes23
- A61K 39/0001Archaeal antigens22
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Systems and methods for administering dermal and transdermal immunotherapy topical application compounds to animals6 Oct 2026US 12,751,998 B2Allibre Animal LLC
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Modular multiplatform system for mrna drug production8 Oct 2026US 2026/0306407 A1BioNTech SE
- Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof8 Oct 2026US 2026/0306419 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pharmaceutical combination for cancer treatment8 Oct 2026US 2026/0306466 A1Miyarisan Pharmaceutical Co., Ltd.
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010